The best test for the world's most expensive disease.
NeuroScreen® testing service is a novel blood-based diagnostic tool for the early detection of Alzheimer's disease - a key factor in treatment efficiency. It uses the body's immune system to track and predict amyloid accumulation in the brain, the pathological manifestation of Alzheimer’s disease.
About
NeuroQuest's team is comprised of medical experts and business professionals from around the world with extensive experience in innovation, development, and clinical research.
Our mission is to provide patients and physicians with NeuroScreen®, our accurate and affordable blood test for screening and monitoring asymptomatic Alzheimer’s disease.
NeuroScreen®
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that gradually impairs memory, cognitive function, and behavior, primarily affecting older adults. It is caused by the accumulation of amyloid-β (Aβ) plaques in the brain, which can begin up to 20 years before the onset of symptoms. While recent data indicate that amyloid-lowering therapeutics are significantly more effective when given to asymptomatic individuals, there has been no effective way to identify these patients until now.
Research shows that as we age, our bodies undergo a range of changes. Our immune system weakens over time, making us more susceptible to new diseases. Experts hypothesized that this natural process facilitates Aβ42 entry into the brain and impairs its clearance. In other words, they believe that Alzheimer's disease might have an immune component to it. NeuroQuest has developed NeuroScreen®, the only blood-based assay that can accurately track Aβ accumulation across all disease stages. The service is based on our unique algorithm that uses immune blood-based biomarkers (leukocytes) to predict Aβ42 levels in the brain, enabling earlier disease detection with ease and efficiency.
Frequently Asked Questions (FAQ)
The problem that NeuroQuest is trying to solve is identifying individuals at risk of Alzheimer's Disease (AD) as early and accurately as possible. Experts agree that early detection of AD is an essential tool of intervention, as it can enhance the efficiency of recently (and soon-to-be) approved drugs for treating and preventing AD from progressing.
While others have attempted to measure p-tau and Aβ plaque accumulation following the onset of symptoms (e.g., cognitive decline, memory loss), NeuroQuest turned to the immune system to predict such accumulation before symptoms appear.
NeuroQuest has developed NeuroScreen® testing service, a novel blood-based diagnostic tool for AD that leverages the immune system's specific response to early indicators. The assay uses peripheral blood immune cells as biomarkers to predict the presence and level of Aβ42 in the brain.
NeuroScreen® testing services offer the only blood-based assay that can track Aβ42 accumulation in the brain, even in asymptomatic individuals, making it an affordable, easy-to-administer diagnostic tool. It is the only blood-based assay that does not rely on any p-tau species and provides significantly higher accuracy at lower cL levels.
Alzheimer’s disease (AD) is a devastating, progressive neurodegenerative disorder that gradually impairs memory, cognitive function, and behavior, primarily affecting older adults. An estimated 7.2 million Americans age 65 and older are living with Alzheimer’s dementia in 2025 (Alzheimer's Association), and more than 55 million people are believed to be living with Alzheimer’s disease or other dementias worldwide (Alzheimer’s Disease International). The number of people with dementia is projected to double by 2040 and more than triple by 2060. The global economic burden of AD and related dementias is projected to reach $16.9 trillion by 2050.
The disease is caused by the accumulation of amyloid-β (Aβ) plaques in the brain, which can begin up to 20 years before the onset of symptoms. Recently approved FDA drugs for treating AD have demonstrated their ability to decrease the brain amyloid load. However, these treatments have shown limited efficacy, as research has shown that once a certain threshold is reached, Aβ42-induced brain damage is irreversible. Recent data indicate that treatments for AD are significantly more effective when given to asymptomatic individuals, but there has been no effective way to identify these patients until now.
NeuroScreen® testing service will change the world by detecting the disease in millions of asymptomatic individuals, preventing the disease from ever taking place.
NeuroScreen® test service offers tremendous value to:
Patients and their families:
-
Enables access to new treatments
-
Reduces cost, time, and impact of tests and delayed diagnosis
-
Enables financial and care planning
-
Facilitates appropriate use and monitoring of medication
Healthcare providers & clinicians:
-
Helps improve patient care
-
Saves costs of repeated and/or multiple tests
-
Reduces cost and impact of inappropriate, ineffective drug use and/or screening tests
-
Reduces ongoing care costs with patients functioning longer
-
Provides easy to administer, accurate diagnostic tool
-
Strengthens diagnostic arsenal
Pharmaceutical companies:
-
Allows for easy and practical identification of asymptomatic individuals most likely to respond to newly developed disease-modifying treatments
-
Reduces drug development costs and time
-
Increased efficiency with earlier, better diagnosis
-
We have partnered with Vikor Scientific to launch a Lab Developed Test (LDT) by the end of 2026. We will simultaneously conduct our clinical validation study to support an FDA 510(k) application, a significant milestone on our path to commercializing NeuroScreen®.
We plan to market our assay for use in skilled nursing facilities and for clinical research by late 2026 - early 2027. In the long run, our vision is to gradually change the standard of care to a point where any person over the age of 55 can easily screen for Alzheimer's through their primary healthcare provider as a customary procedure.
“The scientific community and the FDA believe that it is critical to identify and study patients with very early Alzheimer's disease before there is too much irreversible injury to the brain. It is in this population that most researchers believe that new drugs have the best chance of providing meaningful benefit to patients.” - Russell Katz, MD, Director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research.
"What we do know is that it’s possible at least to delay the onset of the symptoms of Alzheimer’s disease and give people more years of healthy life.” - Dr. Randall J. Bateman, Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine.